Multiple Sclerosis | Current Treatment: Physician Insights | EU5 | 2022

A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have received EU approval and have launched in the crowded MS market. Given the rapid pace of change in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and likely positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and newly launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescriber choice.

Questions Answered

• How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, active secondary-progressive, nonactive secondary-progressive, and primary-progressive) treated today?
• How do product shares differ across lines of therapy? Are high-efficacy therapies factoring more into early-line treatment decisions?
• How do EMA label restrictions and country-specific guidelines impact prescribing freedom in the European MS markets? What is the size of the eligible population based on certain labels, according to neurologists?
• How has neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
• What are neurologists’ opinions of the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets Covered: France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.

Key drugs covered: Aubagio, glatiramer acetate, Gilenya, Interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Zeposia, Vumerity

Key companies: Biogen, Bristol Myers Squibb, Janssen, Merck KGaA, Novartis, Roche, Sanofi Genzyme, Teva, Viatris

Key insights provided:

• Factors influencing disease management and treatment decisions.
• Drivers and constraints of treatment selection.
• Physician-reported treatment practices and brand-level patient shares.
• Rationale for changes in treatment approach.
• Physician insight on persistency and compliance.
• Physician-reported recent/anticipated changes in brand usage or treatment approach.